Skip to main content
Young businesswoman using a digital tablet while standing in front of windows in office Young businesswoman using a digital tablet while standing in front of windows in office Young businesswoman using a digital tablet while standing in front of windows in office

ProAct
Resources

 

Updates to the Adult Vaccination Schedule

Updates to the Adult Vaccination Schedule hero image

On February 17, 2022, the U.S. Advisory Committee on Immunization Practices' (ACIP) recommended vaccination schedule for U.S. adults 19 years of age and older was shared with some important changes to zoster (shingles), pneumococcal,…

US Government To Provide Free At Home COVID-19 Tests

US Government To Provide Free At Home COVID-19 Tests hero image

The US Government has launched a website that allows for every home in the US to order four (4) free at-⁠home COVID-⁠19 tests.…

Coverage of Antiviral Agents Paxlovid and Molnupiravir

Coverage of Antiviral Agents Paxlovid and Molnupiravir hero image

Recently, the FDA approved the first COVID-19 oral antiviral agents. Pfizer’s Paxlovid® (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) and Merck’s molnupiravir have been granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) in the treatment of mild-to-moderate COVID-19 for people at high risk for progression to severe COVID-19.…

The CDC Updated Recommendations Regarding Interval Between Pfizer Vaccine and Booster Dose

The CDC Updated Recommendations Regarding Interval Between Pfizer Vaccine and Booster Dose hero image

On January 4, 2022, the CDC updated recommendations regarding the interval between a primary series of the Pfizer/BioNTech COVID-19 vaccine and a booster dose. …

FDA approves first COVID-19 oral antiviral

FDA approves first COVID-19 oral antiviral hero image

The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.…

ProAct Logo ProAct Logo ProAct Logo
mobile image tablet image desktop image
Benny, the Chat Bot Greeter